'Daiichi is buying into the development of MK-6070, a trispecific T-cell engager that Merck acquired when it bought Harpoon for $650 million earlier this year. MK-6070, formerly known as HPN328, is designed to bind CD3 on T cells and DLL3 on tumor cells. The third domain binds albumin to extend the half-life.'
#Immunology #Immunotherapy

https://www.fiercebiotech.com/biotech/merck-advances-lung-cancer-attack-pocketing-170m-daiichi-and-plotting-adc-trispecific-combo